Zenith Drugs
NSE: ZENITHDRUG · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Zenith Drugs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Zenith Drugs Ltd is an Indian pharmaceutical company incorporated in 2000 that specialises in the manufacturing and trading of healthcare drugs and pharmaceutical formulations. The company operates across diverse segments including branded generics, institutional supply, and third-party contract manufacturing.
Business Model
The company generates revenue through a multi-channel approach, encompassing the marketing of branded generic medicines, institutional and government contracts, and third-party job work manufacturing. Additionally, it leverages merchant dealers to facilitate the export of its pharmaceutical products.
Growth Outlook
Growth is expected to be driven by the expansion of its institutional business and the scaling of its third-party manufacturing capabilities. The company continues to explore export opportunities through merchant networks to broaden its market reach.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality control standards and evolving pharmaceutical regulations in both domestic and international markets.
- Pricing Pressure. Intense competition in the generic drug segment and government price controls on essential medicines may impact profit margins.
- Supply Chain Volatility. Fluctuations in the cost and availability of active pharmaceutical ingredients (APIs) could disrupt manufacturing operations.
Start your research today
Unlock AI insights, financials, peers and live data on Zenith Drugs and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Zenith DrugsZENITHDRUG | ₹84 Cr | — | — | — | 7.0% | — | — | -38.1% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Mar 2026
Financials
Zenith Drugs
NSE: ZENITHDRUG · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Zenith Drugs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Zenith Drugs Ltd is an Indian pharmaceutical company incorporated in 2000 that specialises in the manufacturing and trading of healthcare drugs and pharmaceutical formulations. The company operates across diverse segments including branded generics, institutional supply, and third-party contract manufacturing.
Business Model
The company generates revenue through a multi-channel approach, encompassing the marketing of branded generic medicines, institutional and government contracts, and third-party job work manufacturing. Additionally, it leverages merchant dealers to facilitate the export of its pharmaceutical products.
Growth Outlook
Growth is expected to be driven by the expansion of its institutional business and the scaling of its third-party manufacturing capabilities. The company continues to explore export opportunities through merchant networks to broaden its market reach.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality control standards and evolving pharmaceutical regulations in both domestic and international markets.
- Pricing Pressure. Intense competition in the generic drug segment and government price controls on essential medicines may impact profit margins.
- Supply Chain Volatility. Fluctuations in the cost and availability of active pharmaceutical ingredients (APIs) could disrupt manufacturing operations.
Start your research today
Unlock AI insights, financials, peers and live data on Zenith Drugs and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026